ReviewFrontiers in oncology2026
Digital intelligence-enabled tumor microbiome research: from mechanistic dissection to clinical translation.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-associated microbiomes are integral components of the tumor microenvironment, modulating tumorigenesis and progression through immune and metabolic pathways. Microbiome data are high-dimensional, sparse, and compositional, which limits conventional analytical approaches. Digital intelligence-an umbrella term encompassing artificial intelligence (AI), machine learning (ML), big-data analytics, and multi-omics integration-has emerged as a powerful paradigm for tumor microbiome research. In this review, we delineate the applications of digital intelligence across the full pipeline: intelligent preprocessing of sequencing data, multi-modal data integration, inference of microbe-host interactions, construction of diagnostic and prognostic models, and discovery of immunotherapy biomarkers. We explicitly distinguish computational association from experimental mechanistic validation and clinical utility, and we critically appraise methodological limitations, including overfitting, data leakage, batch effects, and the scarcity of external prospective validation. Microbiome-related biomarkers are framed as prognostic, predictive, or dynamic, and we caution against equating retrospective performance with clinical value. Finally, we discuss current challenges-data standardization, model interpretability, and ethical privacy-and future directions, including spatial and single-cell microbiomics, FMT-based interventions, and prospectively validated clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.